{"doi":"10.18632/oncotarget.27975","title":"Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity","abstract":"// Viola Ellison 1 , George K. Annor 1 , 2 , Clara Freedman 1 , Gu Xiao 1 , Devon Lundine 1 , 2 , Elzbieta Freulich 3 , Carol Prives 3 and Jill Bargonetti 1 , 2 , 4 1 The Department of Biological Sciences, Hunter College, City University of New York, New York, NY, USA 2 The Graduate Center Biology and Biochemistry Programs, City University of New York, New York, NY, USA 3 Department of Biological Sciences, Columbia University, New York, NY, USA 4 Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY, USA Correspondence to: Jill Bargonetti, email: bargonetti@genectr.hunter.cuny.edu Keywords: mutant p53; gain-of-function; oligomerization; DNA replication; frame-shift Received: March 11, 2021     Accepted: May 15, 2021     Published: June 08, 2021 Copyright: © 2021 Ellison et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT We recently documented that gain-of-function (GOF) mutant p53 (mtp53) R273H in triple negative breast cancer (TNBC) cells interacts with replicating DNA and PARP1. The missense R273H GOF mtp53 has a mutated central DNA binding domain that renders it unable to bind specifically to DNA, but maintains the capacity to interact tightly with chromatin. Both the C-terminal domain (CTD) and oligomerization domain (OD) of GOF mtp53 proteins are intact and it is unclear whether these regions of mtp53 are responsible for chromatin-based DNA replication activities. We generated MDA-MB-468 cells with CRISPR-Cas9 edited versions of the CTD and OD regions of mtp53 R273H. These included a frame-shift mtp53 R273H f s387, which depleted mtp53 protein expression; mtp53 R273HΔ381-388, which had a small deletion within the CTD; and mtp53 R273HΔ347-393, which had both the OD and CTD regions truncated. The mtp53 R273HΔ347-393 existed exclusively as monomers and disrupted the chromatin interaction of mtp53 R273H. The CRISPR variants proliferated more slowly than the parental cells and mt53 R273H f s387 showed the most extreme phenotype. We uncovered that after thymidine-induced G1/S synchronization, but not hydroxyurea or aphidicholin, R273H f s387 cells displayed impairment of S-phase progression while both R273HΔ347-393 and R273HΔ381-388 displayed only moderate impairment. Moreover, reduced chromatin interaction of MCM2 and PCNA in mtp53 depleted R273H f s387 cells post thymidine-synchronization revealed delayed kinetics of replisome assembly underscoring the slow S-phase progression. Taken together our findings show that the CTD and OD domains of mtp53 R273H play critical roles in mutant p53 GOF that pertain to processes associated with DNA replication.","journal":"Oncotarget","year":2021,"id":206749,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9552,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":742170,"name":"George K. Annor","orcid":"0000-0003-2598-1012","position":1,"is_corresponding":false},{"id":791673,"name":"Clara Freedman","orcid":null,"position":2,"is_corresponding":false},{"id":430127,"name":"Gu Xiao","orcid":"0000-0001-8433-9121","position":3,"is_corresponding":false},{"id":742171,"name":"Devon Lundine","orcid":"0000-0003-4845-3116","position":4,"is_corresponding":false},{"id":791674,"name":"Elzbieta Freulich","orcid":null,"position":5,"is_corresponding":false},{"id":62210,"name":"Carol Prives","orcid":"0000-0003-1846-5562","position":6,"is_corresponding":false},{"id":430129,"name":"Jill Bargonetti","orcid":"0000-0003-2692-0991","position":7,"is_corresponding":false},{"id":742173,"name":"Viola Ellison","orcid":"0000-0002-4275-5570","position":0,"is_corresponding":true}],"reference_count":74,"raw_metadata":null,"created_at":"2026-07-18T23:51:41.571653Z","pmid":"34136083","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}